It is gratifying that channelopathies are moving more centre stage and these two articles and accompanying editorial take the fascinating story further in respect of illustrating the reverse side of the same coin --the coin in this case being the potassium channel in the pancreatic beta cell. It has been known for over a decade that neonatal hyperinsulinism is due to failure to close the inwardly rectifying potassium channel in the pancreatic beta cell leading, through a linked series of intracellular events, to dysregulation or inappropriate secretion of insulin. In characterizing the defect at the cellular level, thoughts were then directed to the possibility of the converse, i.e. failure to secrete insulin by loss of function of the pancreatic potassium cells. This would then cause diabetes --this hypothesis was subsequently con¢rmed and the two papers detail further important research in characterizing defects at the molecular level and also response to novel therapies in neonatal diabetes due to defects in the potassium channel. The ¢rst research paper identi¢es mutations in the sulphonyl urea receptor protein --this receptor normally functions to open the potassium channel after activation by binding or hydrolysis of nucleotides to it. The mutations cause overstimulation of the potassium channel leading to impaired insulin secretion. However, they still remain sensitive to the e¡ects of sulphonyl urea blockade which closes the potassium channel and restores insulin secretion. Hitherto most of patients with neonatal diabetes have been investigated for mutations in the Kir6.2 subunit protein of the potassium channel and this class of mutation appears more common. Either way both types of mutation are amenable to treatment with sulphonyl ureas and the second paper details the success of this approach. Of 49 patients with neonatal diabetes, 44 were successfully switched from insulin to sulphonyl ureas. The innovative use of sulphonylureas to treat Type 1 diabetes is based on this new understanding of the regulation of the potassium channel and is indicative of the utility of pharmacogenetics to identify patients who may bene¢t from speci¢c targeted treatments. As the editorial highlights --inherited disorders as ¢rst postulated by Garrod over a century ago shed much light and provide insights into pathological and normal physiological processes.
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Disturbances in the cations --calcium and magnesium --of clinical severity have now been described in patients on proton pump inhibitors. The article describes two patients who presented with carpo-pedal spasms in association with severe hypomagesaemia and hypocalcaemia without a compensatory increase in parathyroid hormone. The ¢rst patient who had been on omeprazole for over a year had a serum calcium of 1.75 mmol/L at presentation with carpopedal spasm. She started calcium replacement, which was later supplemented with magnesium on demonstrating a low serum magnesium of 0.4 mmol/L. The omeprazole was replaced by ranitidine 14 months later, which brought about a normalization of the serum magnesium and urine magnesium. Reintroduction of another proton-pump inhibitor caused the serum magnesium to fall again requiring an increase in supplemental magnesium.
Similar trends in serum calcium and magnesium were observed in a second patient as a consequence of omeprazole therapy --discontinuation of therapy or replacement with ranitidine restoring normal levels. The case reports are accompanied by ¢gures detailing the trends in serum calcium and magnesium and daily magnesium excretion in association with medication. De¢ciency of vitamin D was excluded but there was a blunt response of parathyroid hormone (PTH) in the face of hypocalcaemia, which would be explained by the co-existing hypomagnesaemia.
The metabolic abnormalities normalized with the withdrawal of proton-pump inhibitors. Although the authors use the ¢gures to demonstrate cause and e¡ect of omeprazole, they o¡er no explanation for the mechanism of hypomagnesaemia and hypocalcaemia and cite only one other case report describing hypocalcaemia during omeprazole therapy. They speculate that these cases represent the tip of the iceberg in relation to metabolic abnormalities and recommend the measurement of magnesium in patients on proton-pump medication.
Helen Losty Department of Clinical Biochemistry, Royal Alexandra Hospital, Paisley
Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis Since the realization in the early 1990s that serum procalcitonin (PCT) may be elevated in patients with infection, there has been a burgeoning interest in its use in a clinical setting, especially to di¡erentiate in£ammation due to bacterial infection from other causes (including viral infection). Many studies have been performed although most are small. The majority of these studies compared serum PCT levels from patients with bacterial infection (e.g. sepsis, meningitis, pneumonia, etc.) and controls with SIRS or other causes of in£amma-tion. Infections were, in the majority, diagnosed by a number of factors including clinical examination, radiology and positive microbiological cultures.
In their meta-analysis, Simon et al. gathered together prospective studies published between 1999 and 2001 comparing serum concentrations of PCT with C-reactive protein (CRP). Twelve studies were deemed appropriate for inclusion. A total of 1386 patients were included,702 of whom were adults. Some of the studies were conducted in an intensive care unit (ICU) environment, but there was some heterogeneity. Linear regression was used to combine data from the individual studies and to create summary receiver operating characteristic (ROC) curves. Signi¢cant differences in favour of PCT were found when the sensitivity and speci¢city data from each paper was combined. Pooled sensitivity for PCT was 85% compared with 78% for CRP, while pooled speci¢city was 83% compared with 60%, although the methodology for 'pooling' this data is unclear. PCT was found to be more accurate than CRP on an ROC plot and by Q value.
The ICU is the setting for the meta-analysis of Uzzan and colleagues. Thirty-three studies (from 1999 to 2004) met inclusion criteria, including 3943 adult patients. Sensitivity for PCT was found to vary from 42 to 97%, while speci¢city varied from 48 to 100%. When compared with CRP, PCT was found to be significantly more accurate, both when comparing odds ratios (14.7 for PCT compared with 5.4 for CRP) and when plotted on an ROC curve and Q value calculated.
van Rossum et al. draw together studies in children and neonates; while they do not attempt to meta-analyse the data, they eloquently summarize the available studies. There is much inconsistency between studies, but PCT seems to be an early, speci¢c marker of severe sepsis in neonates. However, neonatal studies are complicated by a transient rise in PCT levels in the ¢rst 48 h of life. Hypoxaemia may also be responsible for increased concentrations. In older children, PCT is most useful in severe sepsis syndromes and may help in di¡erentiating pyelonephritis from urinary infection of the lower tract. There are inconsistencies in the results of PCT use in chest infections, especially where pretreatment with antibiotics has occurred.
There are many potential di⁄culties in interpreting results of studies that investigate diagnostic tests, especially where there is absence of a true gold standard. It is unsurprising, therefore, that methodology for de¢ni-tion of 'infected' patients varied between studies. Indeed, many of these studies are small and research methods were poorer than, for example, a randomized controlled trial. Blinding was not routine in many studies. Some studies pooled serial values, while others considered only an early sample. In each study, PCT was measured by the same commercially available assay, while CRP testing methodology varied. In addition, di¡erent studies used di¡erent cut-o¡ values for PCT and/or CRP. Furthermore, in the meta-analysis of Simon et al., the larger studies showed a smaller difference in sensitivity and speci¢city than smaller studies (Knudsen and Kristiansen, Clin Inf Dis 2005; 40:1372) .
All three reviews concur that PCT has high (but not infallible) sensitivity and speci¢city for severe bacterial infection. However, the role of PCT is not yet entirely clear. It is likely that further economic and cost-e¡ec-tiveness studies will be needed if PCT is to become the choice serum marker of severe infection in hospitals.
James J Clayton
Medical Microbiology, Leeds Teaching Hospitals NHS Trust Piscator I n a previous life Piscator, under the guise of Journal Watch, drew attention to the sterling work of scienti¢c detectives in the emerging ¢eld of paleopathology.
I
t was in relation to the chemical analysis of hair belonging to a previous British regent to determine whether an environmental toxin was responsible for precipitating episodes of madness thought to be associated with variegate porphyria. Not to be outdone, our colleagues in mainland Europe have now sought to determine whether a previous incumbent of the top position in the Holy Roman Empire (which preceded the current European Union by a few centuries) was a¥icted by gout. The investigators chose to publish their results in a periodical from the other side of the Atlantic --a land mass which had only just been discovered, before the reign of Charles V (NEJM 2006; 355: 516) . This Holy Roman Emperor endured extreme arthritic pain most of his life, and his physical su¡ering had rami¢cations for the colonies and territories over which he ruled. His physicians were of the opinion that his arthritic pain was gout, and it is only now, with access to radiography, crystallography and biochemical analyses, that the suspicions of generations of royal physicians can be con¢rmed. It helped that when he passed away his corpse underwent spontaneous mummi¢cation. In addition, his little ¢nger was preserved separately outside the co⁄n. Recent examination of the said little ¢nger revealed massive gouty tophi and demonstrable urate deposits. Both histological and electron microscopies were undertaken, and a 20 mm specimen was submitted for uric acid analysis using uricase-based commercial reagent. Biochemical analysis con¢rmed signi¢cant urate concentration. Gout is enjoying a revival as a disease of Western a¥uence, but has been around since the days of the original Roman Empire. Will all this 'cold case' work see laboratories deluged by specimens from subjects whose D.o.B. will cause the lab computer to crash? Charles V passed on in 1556: most lab data bases have di⁄culty accommodating two centuries, never mind ¢ve! R ather than imbibing copious amounts of Rioja, Charles might have been better quenching his thirst with a good old 'cuppa'. It will come as no surprise to the nation of tea drinkers that the beverage has been con¢rmed as an e⁄cient stress buster (Psychopharmacology, 30 September 2006, online publication). This was demonstrated in an excellently conceived randomized, double-blind, placebo-controlled trial of the e¡ects of tea in dealing with psychophysiological stress. The investigators were mindful of the anecdotal bene¢ts of tea as a de-stressor, but acknowledged that this had never been subjected to scienti¢c scrutiny. Seventy-¢ve young male tea drinkers were recruited to the study and randomized to a placebo or to a beverage concocted from the constituents of black tea. The e¡ects of a six-week period of black tea consumption on subjective, cardiovascular, cortisol and platelet response to acute stress were
